Aspire Biopharma Holdings (ASBP) Common Equity (2021 - 2026)
Aspire Biopharma Holdings' (ASBP) quarterly Common Equity came in at $3.9 million in Q1 2026, up 148.64% year-on-year from $1.6 million in Q1 2025, and up 160.67% on a QoQ basis from -$6.4 million in Q4 2025.
Aspire Biopharma Holdings (ASBP) Common Equity (2021 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has 6 years of Common Equity data on file, last reported at $3.9 million in Q1 2026.
- On a quarterly basis, Common Equity rose 148.64% year-over-year to $3.9 million in Q1 2026; TTM through Mar 2026 was $3.9 million, a 148.64% increase from a year earlier, with the FY2025 full-year figure at -$6.4 million, down 314.02% from the prior year.
- Common Equity for Q1 2026 stood at $3.9 million, up from -$6.4 million in the prior quarter.
- Over the last five years, Common Equity for ASBP reached as high as $3.9 million in Q1 2026 and fell as low as -$11.5 million in Q3 2025.
- Historically, Common Equity has averaged -$4.9 million across 5 years, with a median of -$6.4 million in 2025.
- Across the five-year window, Common Equity plunged 2092089.68% in 2022 and jumped 148.64% in 2026, its largest moves.
- Year by year, Common Equity stood at -$9.9 million in 2022, then surged by 95.09% to -$487861.0 in 2023, then tumbled by 215.68% to -$1.5 million in 2024, then tumbled by 314.02% to -$6.4 million in 2025, then jumped by 160.67% to $3.9 million in 2026.
- Per Business Quant data, the three most recent Common Equity figures were $3.9 million in Q1 2026, -$6.4 million in Q4 2025, and -$11.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | 251.12 Mn |
| 2 | Nanobiotix | 1,933.35 Bn | 1,933.29 Bn | - | -98.34 Mn |
| 3 | Akari Therapeutics | 1,063.56 Bn | 1,063.56 Bn | - | 14.38 Mn |
| 4 | BeOne Medicines | 468.54 Bn | 463.75 Bn | 1.35 Bn | 4.76 Bn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.20 Bn | 2.59 Bn | 19.36 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn | 31.42 Bn |
| 7 | Belite Bio | 63.57 Bn | 63.57 Bn | - | 795.79 Mn |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.75 Bn | 34.74 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Aspire Biopharma Holdings | 1.10 Mn | -722,113.72 | 5,750.00 | 3.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.87 Mn |
| Dec 31, 2025 | -6.38 Mn |
| Sep 30, 2025 | -11.47 Mn |
| Jun 30, 2025 | -9.62 Mn |
| Mar 31, 2025 | -7.95 Mn |
| Dec 31, 2024 | -1.54 Mn |
| Sep 30, 2024 | -774,378.00 |
| Jun 30, 2024 | -558,109.00 |
| Mar 31, 2024 | -489,747.00 |
| Dec 31, 2023 | -487,861.00 |
| Sep 30, 2023 | -62,954.00 |
| Jun 30, 2023 | 261,788.00 |
| Mar 31, 2023 | -10.26 Mn |
| Dec 31, 2022 | -9.94 Mn |
| Sep 30, 2022 | -9.62 Mn |
| Jun 30, 2022 | -9.37 Mn |
| Mar 31, 2022 | -9.05 Mn |
| Dec 31, 2021 | -475.00 |